Intellectual property
The patent application for TL-532 and a new family of TLR3 ligands was filed by TOLLYS in 2018 (EP 18305561).
Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE
The patent application for TL-532 and a new family of TLR3 ligands was filed by TOLLYS in 2018 (EP 18305561).
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE